Mueller Yolanda K, Bastard Mathieu, Nkemenang Patrick, Comte Eric, Ehounou Geneviève, Eyangoh Sara, Rusch Barbara, Tabah Earnest Njih, Trellu Laurence Toutous, Etard Jean-Francois
Epicentre, Paris, France.
Médecins Sans Frontières, Geneva, Switzerland.
PLoS Negl Trop Dis. 2016 Apr 5;10(4):e0004593. doi: 10.1371/journal.pntd.0004593. eCollection 2016 Apr.
Access to laboratory diagnosis can be a challenge for individuals suspected of Buruli Ulcer (BU). Our objective was to develop a clinical score to assist clinicians working in resource-limited settings for BU diagnosis.
METHODODOLOGY/PRINCIPAL FINDINGS: Between 2011 and 2013, individuals presenting at Akonolinga District Hospital, Cameroon, were enrolled consecutively. Clinical data were collected prospectively. Based on a latent class model using laboratory test results (ZN, PCR, culture), patients were categorized into high, or low BU likelihood. Variables associated with a high BU likelihood in a multivariate logistic model were included in the Buruli score. Score cut-offs were chosen based on calculated predictive values. Of 325 patients with an ulcerative lesion, 51 (15.7%) had a high BU likelihood. The variables identified for the Buruli score were: characteristic smell (+3 points), yellow color (+2), female gender (+2), undermining (+1), green color (+1), lesion hyposensitivity (+1), pain at rest (-1), size >5cm (-1), locoregional adenopathy (-2), age above 20 up to 40 years (-3), or above 40 (-5). This score had AUC of 0.86 (95%CI 0.82-0.89), indicating good discrimination between infected and non-infected individuals. The cut-off to reasonably exclude BU was set at scores <0 (NPV 96.5%; 95%CI 93.0-98.6). The treatment threshold was set at a cut-off ≥4 (PPV 69.0%; 95%CI 49.2-84.7). Patients with intermediate BU probability needed to be tested by PCR.
CONCLUSIONS/SIGNIFICANCE: We developed a decisional algorithm based on a clinical score assessing BU probability. The Buruli score still requires further validation before it can be recommended for wide use.
对于疑似布氏杆菌溃疡(BU)的个体而言,获得实验室诊断可能是一项挑战。我们的目标是制定一个临床评分系统,以协助在资源有限环境中工作的临床医生进行BU诊断。
方法/主要发现:2011年至2013年期间,连续纳入喀麦隆阿科诺林加区医院就诊的个体。前瞻性收集临床数据。基于使用实验室检测结果(ZN、PCR、培养)的潜在类别模型,将患者分为高或低BU可能性类别。多变量逻辑模型中与高BU可能性相关的变量被纳入布氏杆菌评分。根据计算出的预测值选择评分临界值。在325例有溃疡性病变的患者中,51例(15.7%)有高BU可能性。为布氏杆菌评分确定的变量为:特征性气味(+3分)、黄色(+2分)、女性性别(+2分)、潜行性破坏(+1分)、绿色(+1分)、病变感觉减退(+1分)、静息痛(-1分)、大小>5cm(-1分)、局部淋巴结病(-2分)、年龄20岁至40岁以上(-3分)或40岁以上(-5分)。该评分的AUC为0.86(95%CI 0.82 - 0.89),表明在感染和未感染个体之间具有良好的区分能力。合理排除BU的临界值设定为评分<0(NPV 96.5%;95%CI 93.0 - 98.6)。治疗阈值设定为临界值≥4(PPV 69.0%;95%CI 49.2 - 84.7)。具有中等BU可能性的患者需要通过PCR检测。
结论/意义:我们基于评估BU可能性的临床评分制定了一种决策算法。布氏杆菌评分在被推荐广泛使用之前仍需要进一步验证。